The chronic kidney disease treatment market size was valued at $32 billion in 2022, and is estimated to reach $47.9 billion by 2032, growing at a CAGR of 4% from 2023 to 2032.CAGR: 4%Current Market Size: USD 32 BillionFastest Growing Region: APACLargest Market: North AmericaProjection Time: 2022-2032Base Year: 2022.
Mounjaro, a weight loss medication, is projected to outpace Ozempic, driven by convincing clinical results and anticipated sales of $27 billion by 2029.
Obesity Drug Mounjaro To Surpass Ozempic With $27 Bn Sales In 2029: Report menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Novo Nordisk's Ozempic (semaglutide) took the weight loss sector by storm in 2023, propelled by strong efficacy and safety data, coupled with social media buzz and celebrity endorsements that elevated the drug to mainstream prominence.